查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1913290

血友病治療市場機會、成長要素、產業趨勢分析及2026年至2035年預測

Hemophilia Treatment Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026 - 2035
出版日期: | 出版商: Global Market Insights Inc. | 英文 163 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

全球血友病治療市場預計到 2025 年將達到 152 億美元，到 2035 年將達到 272 億美元，年複合成長率為 6.1%。

血友病治療市場-IMG1

由於A型血友病率不斷上升、預防性治療方法被廣泛接受以及先進治療創新技術的加速應用，市場持續擴張。血友病治療的重點在於控制凝血因子缺乏引起的出血性疾病，以維持穩定的凝血功能並最大限度地降低出血風險。從被動治療轉向以預防為主的長期疾病管理模式也是推動市場成長的因素之一。治療持久性、劑量準確性和患者便利性的不斷改進正在提高治療依從性和療效。人們日益關注提高生活品質和減少長期併發症，這進一步增強了已開發國家和新興國家醫療保健系統的需求。此外，能夠提供持續治療益處並減輕治療負擔的創新技術正在重塑治療方法選擇，並推動全球市場成長。

市場覆蓋範圍
開始年份 2025
預測年份 2026-2035
起始值 152億美元
預測金額 272億美元
複合年成長率 6.1%

預計到2025年， A型血友病市場將佔76.6%的市場佔有率，並在2034年之前以6%的複合年成長率成長。該細分市場之所以能保持主導地位，是因為其在全球範圍內的高發病率催生了對先進治療方案的巨大需求，治療方法方案旨在解決凝血因子缺乏問題。大規模的患者群體持續推動現有療法和新興治療方法的廣泛應用，從而促進了該細分市場收入的持續成長。

預計到2025年，重組凝血因子療法市場規模將達到71億美元，到2035年將以6.2%的複合年成長率成長。這些治療方法因其穩定的供應、不斷提高的安全標準和改善的治療效果而持續廣泛認可。持續的創新，例如延長產品作用時間和減少給藥頻率，進一步鞏固了其強大的市場地位。

預計到2025年，北美血友病治療市場佔有率將達到44.2%，這主要得益於先進的醫療基礎設施、高診斷率、新型治療方法的早期應用以及健全的醫保報銷體系。此外，該地區也受惠於廣泛的臨床研究活動和完善的患者支持體系。

目錄

第1章調查方法和範圍

第2章執行摘要

第3章業界考察

  • 生態系分析
  • 產業影響因素
    • 促進要素
      • 血友病和出血性疾病的盛行率不斷上升
      • 轉向預防性和個人化治療
      • 非因子和基因治療的進展
      • 改善新興市場的醫療服務取得和診斷
    • 產業潛在風險與挑戰
      • 高成本和負擔能力障礙
      • 複雜的監管和生產要求
    • 市場機遇
      • 拓展基因治療和根治性方法
      • 數位健康整合與居家照護
  • 成長潛力分析
  • 科技趨勢
    • 當前技術趨勢
    • 新興技術
  • 監管環境
    • 北美洲
    • 歐洲
    • 亞太地區
  • 未來市場趨勢
  • 管道分析
  • 波特五力分析
  • PESTEL 分析

第4章 競爭情勢

  • 介紹
  • 公司市佔率分析
  • 企業矩陣分析
  • 主要市場公司的競爭分析
  • 競爭定位矩陣
  • 重大進展
    • 併購
    • 夥伴關係與合作
    • 新產品發布
    • 擴張計劃

第5章 依疾病類型分類的市場估計與預測，2022-2035年

  • A型血友病A
    • 嚴重
    • 緩和
    • 溫和的
  • B型血友病
    • 嚴重
    • 緩和
    • 溫和的
  • 其他疾病類型

第6章 2022-2035年按產品分類的市場估算與預測

  • 重組凝血因子
    • 因子 VIII
    • 因子九
  • 血漿來源的凝血因子
    • 因子 VIII
    • 因子九
  • 延長半衰期產物
    • 因子 VIII
    • 因子九
  • 去氨加壓素
  • 抗纖溶
  • 基因治療產品
  • 其他產品

7. 按病患類型分類的市場估計與預測，2022-2035 年

  • 兒童
    • 0至4歲
    • 5至13歲
    • 14至18歲
  • 成人版
    • 19至44歲
    • 45歲或以上

8. 按治療方法的市場估計與預測，2022-2035 年

  • 預防性給藥
  • 一經請求

9. 按治療方法的市場估算和預測，2022-2035 年

  • 因子替代療法
  • 非因子替代療法

第10章 依行政途徑分類的市場估計與預測，2022-2035年

  • 注射
  • 滴鼻劑
  • 口服

第11章 依最終用途分類的市場估計與預測，2022-2035年

  • 醫院
  • 診所
  • 血友病治療中心
  • 其他最終用戶

第12章 2022-2035年各地區市場估算與預測

  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 荷蘭
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳洲
    • 韓國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第13章：公司簡介

  • Bayer Healthcare
  • Biogen
  • BioMarin Pharmaceutical
  • Biotest
  • CSL Behring
  • Ferring
  • Genentech
  • Kedrion
  • Novo Nordisk
  • Octapharma
  • Pfizer
  • Sanofi
  • Swedish Orphan Biovitrum
  • Takeda Pharmaceutical
簡介目錄
Product Code: 2772

The Global Hemophilia Treatment Market was valued at USD 15.2 billion in 2025 and is estimated to grow at a CAGR of 6.1% to reach USD 27.2 billion by 2035.

Hemophilia Treatment Market - IMG1

The market continues to expand as a result of the rising incidence of hemophilia A and B, broader acceptance of preventive treatment approaches, and accelerating adoption of advanced therapeutic innovations. Hemophilia treatments focus on managing bleeding disorders caused by deficiencies in clotting factors by supporting stable coagulation and minimizing bleeding risks. Market growth is also being shaped by the transition toward long-term disease management models that prioritize prevention over reactive care. Continuous improvements in treatment durability, dosing precision, and patient convenience are enhancing adherence and outcomes. The growing focus on improving daily quality of life and reducing long-term complications is further strengthening demand across developed and emerging healthcare systems. Additionally, innovations aimed at reducing treatment burden while delivering sustained therapeutic protection are reshaping treatment preferences and reinforcing market momentum globally.

Market Scope
Start Year2025
Forecast Year2026-2035
Start Value$15.2 Billion
Forecast Value$27.2 Billion
CAGR6.1%

The hemophilia A segment accounted for a 76.6% share in 2025 and is expected to grow at a CAGR of 6% through 2034. This segment maintains leadership due to its significantly higher prevalence worldwide and the substantial demand generated for advanced therapeutic solutions addressing clotting factor deficiencies. The large patient base continues to support strong uptake of established and emerging treatment options, contributing to sustained revenue growth within this segment.

The recombinant factor concentrates segment generated USD 7.1 billion in 2025 and is anticipated to grow at a CAGR of 6.2% through 2035. These therapies remain widely preferred due to consistent supply reliability, enhanced safety standards, and improved treatment outcomes. Ongoing innovation focused on extending product longevity and reducing administration frequency continues to reinforce their strong market position.

North America Hemophilia Treatment Market held 44.2% share in 2025, supported by advanced healthcare infrastructure, high diagnosis rates, early adoption of novel therapies, and strong reimbursement frameworks. The region also benefits from extensive clinical research activity and well-established patient support ecosystems.

Key companies active in the Global Hemophilia Treatment Market include Takeda Pharmaceutical, Novo Nordisk, CSL Behring, Pfizer, Sanofi, Genentech, Bayer Healthcare, Swedish Orphan Biovitrum, Octapharma, BioMarin Pharmaceutical, Biogen, Kedrion, Biotest, and Ferring. Companies operating in the Global Hemophilia Treatment Market are strengthening their market position through sustained investment in research and development, with a strong focus on next-generation therapies that improve durability and patient convenience. Strategic collaborations and licensing agreements are being used to accelerate innovation pipelines and expand geographic reach. Manufacturers are also enhancing patient engagement through education initiatives, treatment support programs, and digital adherence tools. Expansion of manufacturing capabilities and optimization of supply chains ensure consistent product availability.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definition
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Data mining sources
    • 1.3.1 Global
    • 1.3.2 Regional/Country
  • 1.4 Base estimates and calculations
    • 1.4.1 Base year calculation
    • 1.4.2 Key trends for market estimation
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
  • 1.6 Forecast model
  • 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis
  • 2.2 Key market trends
    • 2.2.1 Regional trends
    • 2.2.2 Disease type trends
    • 2.2.3 Product trends
    • 2.2.4 Patient trends
    • 2.2.5 Treatment regime trends
    • 2.2.6 Therapy trends
    • 2.2.7 Route of administration trends
    • 2.2.8 End Use trends
  • 2.3 CXO perspectives: Strategic imperatives
    • 2.3.1 Key decision points for industry executives
    • 2.3.2 Critical success factors for market players
  • 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing prevalence of hemophilia and bleeding disorders
      • 3.2.1.2 Shift toward prophylactic and personalized therapies
      • 3.2.1.3 Advancements in non-factor and gene therapies
      • 3.2.1.4 Improved access and diagnosis in emerging markets
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 High cost and affordability barriers
      • 3.2.2.2 Complex regulatory and manufacturing requirements
    • 3.2.3 Market opportunities
      • 3.2.3.1 Expansion of gene therapy and curative approaches
      • 3.2.3.2 Digital health integration and home-based care
  • 3.3 Growth potential analysis
  • 3.4 Technology landscape
    • 3.4.1 Current technological trends
    • 3.4.2 Emerging technologies
  • 3.5 Regulatory landscape
    • 3.5.1 North America
    • 3.5.2 Europe
    • 3.5.3 Asia Pacific
  • 3.6 Future market trends
  • 3.7 Pipeline analysis
  • 3.8 Porter's analysis
  • 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2025

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Key developments
    • 4.6.1 Merger and acquisition
    • 4.6.2 Partnership and collaboration
    • 4.6.3 New product launches
    • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Disease Type, 2022 - 2035 ($ Mn)

  • 5.1 Key trends
  • 5.2 Hemophilia A
    • 5.2.1 Severe
    • 5.2.2 Moderate
    • 5.2.3 Mild
  • 5.3 Hemophilia B
    • 5.3.1 Severe
    • 5.3.2 Moderate
    • 5.3.3 Mild
  • 5.4 Other disease types

Chapter 6 Market Estimates and Forecast, By Product, 2022 - 2035 ($ Mn)

  • 6.1 Key trends
  • 6.2 Recombinant factor concentrates
    • 6.2.1 Factor VIII
    • 6.2.2 Factor IX
  • 6.3 Plasma-derived factor concentrates
    • 6.3.1 Factor VIII
    • 6.3.2 Factor IX
  • 6.4 Extended half-life products
    • 6.4.1 Factor VIII
    • 6.4.2 Factor IX
  • 6.5 Desmopressin
  • 6.6 Antifibrinolytic agents
  • 6.7 Gene therapy products
  • 6.8 Other products

Chapter 7 Market Estimates and Forecast, By Patient, 2022 - 2035 ($ Mn)

  • 7.1 Key trends
  • 7.2 Pediatric
    • 7.2.1 0 to 4
    • 7.2.2 5 to 13
    • 7.2.3 14 to18
  • 7.3 Adult
    • 7.3.1 19-44
    • 7.3.2 45+

Chapter 8 Market Estimates and Forecast, By Treatment Regime, 2022 - 2035 ($ Mn)

  • 8.1 Key trends
  • 8.2 Prophylaxis
  • 8.3 On demand

Chapter 9 Market Estimates and Forecast, By Therapy, 2022 - 2035 ($ Mn)

  • 9.1 Key trends
  • 9.2 Factor replacement therapy
  • 9.3 Non-factor replacement therapy

Chapter 10 Market Estimates and Forecast, By Route of Administration, 2022 - 2035 ($ Mn)

  • 10.1 Key trends
  • 10.2 Injectable
  • 10.3 Nasal spray
  • 10.4 Oral

Chapter 11 Market Estimates and Forecast, By End Use, 2022 - 2035 ($ Mn)

  • 11.1 Key trends
  • 11.2 Hospitals
  • 11.3 Clinics
  • 11.4 Hemophilia treatment centers
  • 11.5 Other end users

Chapter 12 Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)

  • 12.1 Key trends
  • 12.2 North America
    • 12.2.1 U.S.
    • 12.2.2 Canada
  • 12.3 Europe
    • 12.3.1 Germany
    • 12.3.2 UK
    • 12.3.3 France
    • 12.3.4 Spain
    • 12.3.5 Italy
    • 12.3.6 Netherlands
  • 12.4 Asia Pacific
    • 12.4.1 China
    • 12.4.2 India
    • 12.4.3 Japan
    • 12.4.4 Australia
    • 12.4.5 South Korea
  • 12.5 Latin America
    • 12.5.1 Brazil
    • 12.5.2 Mexico
    • 12.5.3 Argentina
  • 12.6 Middle East and Africa
    • 12.6.1 South Africa
    • 12.6.2 Saudi Arabia
    • 12.6.3 UAE

Chapter 13 Company Profiles

  • 13.1 Bayer Healthcare
  • 13.2 Biogen
  • 13.3 BioMarin Pharmaceutical
  • 13.4 Biotest
  • 13.5 CSL Behring
  • 13.6 Ferring
  • 13.7 Genentech
  • 13.8 Kedrion
  • 13.9 Novo Nordisk
  • 13.10 Octapharma
  • 13.11 Pfizer
  • 13.12 Sanofi
  • 13.13 Swedish Orphan Biovitrum
  • 13.14 Takeda Pharmaceutical